Upcoming Ex-Dividend Dates for CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular
Upcoming Ex-Dividend Dates: CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular will trade ex-dividend on 11/20/25, with respective dividends of $0.22, $0.88, and $0.20 scheduled for payment in December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of CenterPoint Energy, Regeneron, and LeMaitre Vascular are expected to open lower by approximately 0.55%, 0.12%, and 0.23%, respectively.
Dividend Aristocrats Contender: LeMaitre Vascular is noted as a future contender for the "Dividend Aristocrats" index, having achieved over 14 years of dividend increases.
Current Stock Performance: As of Tuesday trading, CenterPoint Energy and Regeneron shares have increased by 1.1% and 1.6%, while LeMaitre Vascular shares have decreased by 1.6%.
Trade with 70% Backtested Accuracy
Analyst Views on LMAT
About LMAT
About the author


- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
- Revenue Beat: LeMaitre Vascular reported $64.45 million in revenue last quarter, a 15.7% year-over-year increase that not only surpassed analyst expectations but also provided strong support for next quarter's EPS guidance, indicating robust growth in the medical device sector.
- Optimistic Market Expectations: This quarter, the market anticipates an 11.4% year-over-year revenue growth for LeMaitre, aligning with the 12% increase recorded in the same quarter last year, reflecting analysts' optimistic outlook despite the company's history of missing Wall Street revenue estimates.
- Peer Performance Insights: In the healthcare equipment and supplies sector, Intuitive Surgical and Baxter reported revenue growth of 23% and 2.9%, respectively, exceeding analyst expectations, which may positively influence LeMaitre's performance by reflecting overall industry trends.
- Stable Stock Price: While the healthcare equipment sector saw an average stock price increase of 6% over the past month, LeMaitre's stock price remained unchanged at $108.97, with an average analyst price target of $111.22, indicating cautious optimism regarding its future growth potential.
- Conference Presentation: LeMaitre Vascular will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2025, at 2:15 PM EDT, showcasing its latest advancements in treating peripheral vascular disease.
- Company Overview: LeMaitre Vascular focuses on providing devices, implants, and services for peripheral vascular disease, a condition affecting over 200 million people globally, highlighting its market potential and social responsibility.
- Product Development: The company develops, manufactures, and markets disposable and implantable vascular devices to meet the needs of its core customers, vascular surgeons, thereby driving business growth and increasing market share.
- Information Access: Additional information can be found on the company’s website www.lemaitre.com, demonstrating its commitment to transparency and effective communication with customers.
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
- Executive Stock Transaction: On March 11, 2026, LeMaitre Vascular's Senior Vice President Trent G Kamke sold 2,625 shares of common stock for approximately $285,000, reflecting a common practice among executives to monetize equity awards while adhering to company trading policies.
- Ownership Changes: Kamke's direct holdings decreased from about 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure, yet he retains 1,353 stock options that can be exercised for additional shares, preserving potential upside alignment with company performance.
- Company Financial Performance: In Q4 2025, LeMaitre reported a 16% year-over-year sales increase to $64.5 million, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's strong growth in the medical device sector.
- Future Outlook: The company anticipates a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's ongoing growth potential in the medical device market, which enhances investor confidence in its future performance.
- Executive Stock Transaction: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, exercised and immediately sold 2,625 shares of common stock on March 11, 2026, for approximately $285,000, indicating executive focus on liquidity.
- Ownership Change: Following the transaction, Kamke's direct holdings decreased to 6,677 shares, reflecting that this sale represented 28.22% of his pre-sale direct holdings, aligning with his recent trading patterns and demonstrating confidence in the market.
- Company Financial Performance: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, showcasing strong pricing power and manufacturing efficiencies that boosted overall performance.
- Future Outlook: The company projects approximately $280 million in full-year sales for 2026, raised its dividend by 25%, and initiated a $100 million buyback program, indicating strong confidence in future growth and commitment to shareholder returns.










